Document is current

Article History

Received: 30 June 2022

Accepted: 1 October 2022

First Online: 18 October 2022

Declarations

:

: Ethics approval for the trial was provided by the Cambridge East Research Ethics Committee (ref: 20/EE/0101). Written informed consent was obtained from all the patients or from a legal representative if they were unable to provide consent.

: All authors have seen and approved the final version and agree to its submission for publication.

: PS is the Chair of the DMC for the ORION-4 study sponsored by the Nuffield Department of Population Health at the University of Oxford, for which he receives fees and expenses. DD is a consultant to the National Institutes of Health, the Food and Drug Administration, and the pharmaceutical and medical device industry on the design, monitoring, and analysis of clinical trials. He receives compensation for serving on several industry-sponsored data and safety monitoring committees including Astra Zeneca, Amgen, Actelion, Bristol Meyers Squib, DalCor, GSK, Merck, Sanofi, Boston Scientific, Medtronic, Mesoblast, Intercept, Duke Clinical Research Institute, and Population Health Research Institute of Hamilton. He holds no stock in any pharmaceutical or device company. JD, RF, DL, MM, NS, AW, JW, and JRE declare that they have no competing interests. None of the authors received any payment to serve on the RECOVERY DMC.